A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs AMG 232 (Primary) ; Dabrafenib; Trametinib
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Amgen
- 14 Feb 2018 Planned primary completion date changed from 15 Apr 2018 to 15 Oct 2019.
- 14 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2017 Planned End Date changed from 1 Jun 2021 to 17 Aug 2021.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History